Hundreds of weight loss and diabetes jab users report pancreas problems | Health
Hundreds of people reported problems with their pancreas associated with weight loss and receiving diabetes injections and led health officials to start a study on side effects.
Some cases of pancreatitis reported to be connected to GLP-1 drugs (Glucagon-like peptide-receptor agonists) have been fatal.
Movement, Pharmaceutical and Health Products Regulatory Agency (MHRA) in acute pancreatitis reports Yellow card schemeFollowing negative reactions to drugs and medical devices in the UK.
Acute pancreatitis It is a sudden inflammation of the pancreas, a cloth that helps digestion behind the stomach. It usually requires hospital entry. Symptoms include abdominal, nausea and severe pain over fire.
PATIENT INFORMATION BROCHURES Pancreatitis for GLP-1 drugs as a “rare ıyla reaction that affects one of 100 patients. So far, the schema Mounjaro, Wegovy, Ozempik and Liraglutide patients using approximately 400 acute pancreatitis reports from patients containing tirzepathide (Mounjaro).
More than one quarter of these cases have been reported in 2025. Since the beginning of the year, there is a 22 acute pancreatitis report after receiving Tirzepathide (Mounjaro) to the yellow card scheme after receiving Semaglutid (Özempic and Wegovy).
A Mhra spokesman said: ında In addition to increasing use, we see an increase in the number of yellow card reports that talk about GLP-1 drugs and acute pancreatitis. ”
Due to the effect of this serious disease on patients, Mhra said he wanted to understand whether there is any genetic factor. Acute pancreatitis hospitalized everyone, these drugs to notify the yellow card scheme encouraged to report. Health professionals are also asked to report to the plan on behalf of their patients.
MHRA will then invite these patients to participate. Yellow Card Biobank StudyGenomics is managed by England. Participants will be asked to give more information with a sample example to be analyzed by scientists.
Although there is no known genetic connection that increases the risk of acute pancreatitis when buying GLP-1 drugs, Mhra said: “Sometimes genes can affect individual experiences when buying a drug, we are more investigating in the context of increasing use of these drugs and acute pancreatitis reports.
Studies have shown that negative reactions to the drug constitute one of six hospital acceptances.
Dr. Alison Cave, Mhra’s chief security officer, said: “Evidence shows that almost one -third of the side effects of drugs can be prevented by bringing genetic tests. Negative drug reactions are estimated to cost NHS only more than £ 2.2 billion per year in hospital stay.”
Mounjaro’s producer Lilly’s spokesman said: “Patient security is Lilly’s most important priority.
Uz We take reports on patient safety seriously and we are actively monitoring, evaluating and reporting security information for all our medicines. Negative events should be reported under Mhra’s yellow card scheme, but may be caused by other factors, including previous conditions.
“Mounjaro (Tirzepathide) Patient information brochure warns that inflammatory pancreas (acute pancreatitis) is a rare side effect (may affect up to 1 in 100 people). In addition, patients advise patients to talk to their doctors or other health professionals before using Mounjaro.
